FDA Issues Final Rules for Prescription Drug Companion Applications

The U.S. Food and Drug Administration has issued its final guidance for prescription drug companion applications. This clarifies how app content is categorized as either FDA-required or promotional labeling, and when apps must be referenced in a drug's official Prescribing Information. The guidance aims to ensure digital tools provide accurate, evidence-based information to patients and healthcare providers, impacting pharmaceutical companies and app developers.